New antibody combo aims to outperform standard therapy in Tough-to-Treat colorectal cancer
NCT ID NCT07702032
First seen Jul 14, 2026 · Last updated Jul 21, 2026 · Updated 3 times
Summary
This phase 3 trial tests whether a new drug called petosemtamab, combined with chemotherapy, works better than the current standard treatment (cetuximab plus chemotherapy) for people with left-sided colorectal cancer that cannot be surgically removed or has spread. The study includes about 960 participants whose tumors have specific genetic markers (RAS and BRAF wild-type). The goal is to see if the new combination can slow cancer growth or shrink tumors more effectively.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- an experimental antibody called petosemtamab combined with chemotherapy
- What this could lead to
- If successful, this could offer a new first-line treatment option for people with a specific type of left-sided colorectal cancer that has spread.
- What could go wrong
- This is an early-phase 3 trial, so results are not yet known. The experimental drug may not prove more effective than the current standard treatment, and side effects could be significant.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LEFT-SIDED COLORECTAL ADENOCARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
PanOncology
RECRUITINGManati, PR, 00674, Puerto Rico
More trials for these conditions
Other studies related to the condition(s) this trial covers.